UCB SA (UCB.BR) Stock Price, Forecast & Analysis
Europe - EBR:UCB - BE0003739530 - Common Stock
UCB.BR Key Statistics, Chart & Performance
The current stock price of UCB.BR is 222.5 EUR. In the past month the price decreased by -11.71%. In the past year, price increased by 23.34%.
UCB.BR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1LLY.MI | ELI LILLY & CO | 53.15 | 703.22B | ||
| LLY.DE | ELI LILLY & CO | 53.13 | 703.03B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.56 | 440.12B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.17 | 393.33B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 17.74 | 384.13B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 13.86 | 237.60B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 13.97 | 239.54B | ||
| SNW.DE | SANOFI | 14.26 | 213.75B | ||
| SAN.PA | SANOFI | 14.24 | 213.49B | ||
| 1SAN.MI | SANOFI | 14.19 | 212.63B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 14.13 | 207.14B | ||
| NOT.DE | NOVARTIS AG-REG | 14.16 | 207.52B |
Related stock screener links
About UCB.BR
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9215
Phone: 3225599999
UCB SA / UCB.BR FAQ
What does UCB do?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale and currently employs 9,378 full-time employees. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
What is the stock price of UCB SA today?
The current stock price of UCB.BR is 222.5 EUR. The price decreased by -6.36% in the last trading session.
What is the dividend status of UCB SA?
UCB SA (UCB.BR) has a dividend yield of 0.39%. The yearly dividend amount is currently 1.36.
How is the ChartMill rating for UCB SA?
UCB.BR has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists UCB stock?
UCB.BR stock is listed on the Euronext Brussels exchange.
What is the market capitalization of UCB stock?
UCB SA (UCB.BR) has a market capitalization of 43.28B EUR. This makes UCB.BR a Large Cap stock.
Who owns UCB SA?
You can find the ownership structure of UCB SA (UCB.BR) on the Ownership tab.
UCB.BR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 83.6% of all stocks.
UCB.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. Both the profitability and the financial health of UCB.BR get a neutral evaluation. Nothing too spectacular is happening here.
UCB.BR Financial Highlights
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 75.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.45% | ||
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| Debt/Equity | 0.29 |
UCB.BR Forecast & Estimates
25 analysts have analysed UCB.BR and the average price target is 233.58 EUR. This implies a price increase of 4.98% is expected in the next year compared to the current price of 222.5.
For the next year, analysts expect an EPS growth of 51.36% and a revenue growth 22.68% for UCB.BR